Recent research has demonstrated that survivors of childhood cancer are at risk for a myriad
of late effects that affect physical and mental quality of life. We discuss the patterns and …

Purpose This review assesses the current state of knowledge regarding preclinical and
clinical pharmacology for brain tumor chemotherapy and evaluates relevant brain tumor …

Purpose Early intensification with methotrexate (MTX) is a key component of acute
lymphoblastic leukemia (ALL) therapy. Two different approaches to MTX intensification exist …

Purpose To determine rates, patterns, and predictors of neurocognitive impairment in adults
decades after treatment for childhood acute lymphoblastic leukemia (ALL). Patients and …

The trial ALL-BFM 95 for treatment of childhood acute lymphoblastic leukemia was designed
to reduce acute and long-term toxicity in selected patient groups with favorable prognosis …

Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for late effects of
cancer therapy. Five-year ALL survivors (< 21 years at diagnosis; n= 5760 eligible, 4151 …

The intensified administration of chemotherapeutic drugs has gradually replaced cranial
radiation therapy (CRT) for the treatment of childhood acute lymphoblastic leukemia (ALL) …

Survivors of childhood cancer frequently experience cancer-related cognitive dysfunction,
commonly months to years after treatment for pediatric brain tumors, acute lymphoblastic …

With advances in therapeutic strategies for common childhood malignancies such as
leukemia, lymphoma, and central nervous system (CNS) tumors, the number of childhood …

Purpose To examine associations among methotrexate pharmacodynamics, neuroimaging,
and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic …